Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

ClinicalTrials.gov ID: NCT00735553

Public ClinicalTrials.gov record NCT00735553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Premenopausal women with symptomatic uterine fibroids will be randomized to either Proellex 25mg or 50mg or placebo for one treatment cycle (four months). Safety and effectiveness between 50 mg versus placebo, and between 25mg and placebo will be analyzed.

Study identification

NCT ID
NCT00735553
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Repros Therapeutics Inc.
Industry
Enrollment
77 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 48 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2008
Primary completion
Jul 31, 2009
Completion
Jul 31, 2009
Last update posted
Aug 20, 2014

2008 – 2009

United States locations

U.S. sites
15
U.S. states
7
U.S. cities
13
Facility City State ZIP Site status
Alabama Clinical Therapeutics Birmingham Alabama 35235
Women's Health Research Phoenix Arizona 85015
Genova Clinical Research, Inc. Tucson Arizona 85741
Women's Health Care at Frost Steet San Diego California 92123
Downtown Women's Health Care Denver Colorado 80218
Visions Clinical Research Boynton Beach Florida 33472
OB-GYN Associates of Mid-Florida, P.A. Leesburg Florida 34748
Miami Research Associates Miami Florida 33143
Insignia Clinical Research Tampa Florida 33613
SC Clinical Research Center Columbia South Carolina 29201
Advanced Research Associates Corpus Christi Texas 78414
Advances in Health Inc. Houston Texas 77030
The Woman's Hospital of Texas, Clinical Research Center Houston Texas 77054
Institute for Women's Health San Antonio Texas 78229
Seven Oaks Women's Ctr. San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00735553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2014 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00735553 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →